The main expected manifestations of overdose include bone marrow suppression, peripheral neuropathy and mucositis. Currently, the antidote is not known to docetaxel. In the case of an overdose the patient should be hospitalized in a specialized unit and closely monitor vital organ function. Patients should be as soon as possible to appoint a tri tren side effects. If necessary – symptomatic therapy.
Interaction with other drugs
Studies in vitro have shown that the drug biotransformation may be changed while the application substances inducing or inhibiting cytochrome system or metabolized by cytochrome system, such as cyclosporine, terfenadine, ketoconazole, erythromycin and troleandomycin. Therefore caution should be exercised with concomitant administration of these drugs, given the opportunity to express interaction.
In vitro drugs strongly bind to proteins, such as erythromycin, diphenhydramine, propranolol, propafenone, phenytoin, salicylate, sulfamethoxazole and sodium valproate, have no effect on protein binding of docetaxel. Dexamethasone has no effect on the degree of binding to plasma proteins docetaxel. Docetaxel has no effect on protein binding of digitoxin.
When used in combination with docetaxel, doxorubicin, docetaxel clearance increases while maintaining its efficacy. In this doxorubicin clearance level and doxorubicinol in plasma not menyaetsya.Klirens carboplatin in combination therapy with docetaxel increases by 50% than when carboplatin monotherapy.
The effects of docetaxel n the pharmacokinetics of the main metabolite of capecitabine and the effect of capecitabine on the pharmacokinetics of docetaxel have been identified.
Taxotere treatment should be carried out only under the supervision of a physician with experience in cancer chemotherapy in a specialized hospital.
There should be careful monitoring of the blood count in patients receiving therapy with Taxotere. If severe neutropenia tri tren side effects during a course of therapy is recommended to reduce dose for subsequent courses or use appropriate symptomatic measures. Continue to follow-up treatment possible after recovery of neutrophils to 1500 cells / mm.
C to identify hypersensitivity reactions, patients should be monitored closely, especially during the first and second infusions. The development of hypersensitivity reactions is possible on the very first minute infusion of Taxotere. Mild symptoms of hypersensitivity (localized redness of the face or skin reactions) do not require interruption of drug administration. Severe hypersensitivity reactions (lowering blood pressure, bronchospasm or generalized rash / erythema), demand the immediate lifting of administration and appropriate therapeutic interventions for relief of these complications. Reuse of Taxotere in these patients is not permitted.
Patients receiving docetaxel monotherapy at 100 mg / m 2, and having a high activity of serum transaminases is more than 1.5 times , combined with increased serum levels of alkaline phosphatase in more than 2.5 times , extremely high risk of developing serious side effects: sepsis, gastrointestinal bleeding, febrile neutropenia, infections, thrombocytopenia, stomatitis and asthenia. Due to such patients with elevated liver function indicators Taxotere recommended . Liver function tests should be determined before the start of therapy and before each subsequent cycle of therapy. Patients with elevated bilirubin and / or increased activity of tri tren side effectsin conjunction with increased levels of alkaline phosphatase more than 6 times the is not recommended to use Taxotere. At the moment, there are no data on the use of Taxotere in combination with other drugs in patients with impaired hepatic function.
In connection with the possibility of fluid retention, the need for careful monitoring of patients with pleural effusion, pericardial or ascites. When edema – the restriction of salt and fluid intake and diuretics.
In the combination therapy Taxotere, doxorubicin and cyclophosphamide risk of developing acute leukemia is comparable to the risk in the treatment regimen containing anthracycline / cyclophosphamide.
Men and women of childbearing age during treatment with Taxotere and for at least three months after cessation of therapy is necessary to use reliable methods of contraception.
Taxotere is an anticancer agent; As in the case of other potentially toxic substances must be careful when applying it and preparing solutions. It is recommended to use these gloves. If you concentrate, premix solution or infusion of Taxotere gets on your skin, it should immediately be washed thoroughly with soap and water. After contact with the concentrate, premix solution or infusion solution of tri tren side effects in the mucous membranes, they should be immediately and thoroughly rinse with water.